EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSSDUG00000000390
Gene Symbol: PDE9A
3 Cross references
185 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSSDUG00000010574
Gene Symbol: PIK3R1
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSSDUG00000008807
Gene Symbol: PIK3R2
3 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSDUG00000008677
Gene Symbol: PIK3R3
3 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSSDUG00000001043
Gene Symbol: PIK3R3
3 Cross references
171 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSDUG00000020441
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSDUG00000017697
Gene Symbol: PIK3R5
4 Cross references
185 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSDUG00000006633
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSSDUG00000018676
Gene Symbol: PLA2G10
1 Cross references
232 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSSDUG00000005374
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasminogen

Ensembl ID : ENSSDUG00000004205
Gene Symbol: PLG
3 Cross references
253 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSDUG00000022935
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).